Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL

NCT00057343 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00057343
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00057343 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospectively Randomized, Phase III, Multicenter, Controlled Trial to Evaluate the Safety and Efficacy of the Zevalin Therapeutic Regimen Plus Rituxan Compared With Rituxan Alone in Patients With Relapsed or Refractory Follicular NHL
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2003
Completion date
Not reported
Enrollment
400
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma